Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

MicroPort MedBot IPO: Forecasts, Peer Comparison and Valuation

MicroPort MedBot IPO: Strong Suite of Surgical Robots Covering Fast-Growing Surgical Specialties

MicroTech Medical IPO: Forecasts and Valuation

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

Shanghai MicroPort MedBot Group / Equity Capital Markets

Shanghai MicroPort MedBot Group (2252 HK)

<a href="https://www.smartkarma.com/entities/shanghai-microport-medbot-group-co-ltd" target="_blank" rel="noopener">Shanghai MicroPort MedBot Group (MMG HK)</a> is a surgical robot company which designs, develops and commercialises surgical robots to assist in performing complex surgical procedures. MicroPort’s product line-up includes three flagship products Toumai (Laparoscopic Surgical Robot), DFVision (3D Electronic Laparoscope) and Honghu (orthopaedic surgical robot) and all three are admitted to the NMPA’s innovative medical device special review and approval procedure (known as Green Path). Toumai and Honghu are currently at the registration approval stage while Honghu has received the NMPA approval recently, and these three products should offer immediate revenue opportunity for the company.The company priced its IPO at HK$43.20 per share, at the upper end of the IPO price range of HK$39.60-43.20 per share and raised net proceed of approx. HK$1,457.4m at a market capitalisation of HK$41.2bn and a post-money Enterprise Value of HK$38.5bn. According to the company, both its HK offering, and international offering were significantly oversubscribed by approx. 164x and 16x respectively.In our previous two insights on the company’s IPO, we discussed the company’s core products and product portfolio, outlook, key financials and the company’s IPO valuation.

Shanghai MicroPort MedBot Group (MMG HK) is a surgical robot company which designs, develops and commercialises surgical robots to assist in performing complex surgical procedures. MicroPort’s product line-up includes three flagship products Toumai (Laparoscopic Surgical Robot), DFVision (3D Electronic Laparoscope) and Honghu (orthopaedic surgical robot) and all three are admitted to the NMPA’s innovative medical device special review and approval procedure (known as Green Path). Toumai and Honghu are currently at the registration approval stage while Honghu has received the NMPA approval recently, and these three products should offer immediate revenue opportunity for the company.The company priced its IPO at HK$43.20 per share, at the upper end of the IPO price range of HK$39.60-43.20 per share and raised net proceed of approx. HK$1,457.4m at a market capitalisation of HK$41.2bn and a post-money Enterprise Value of HK$38.5bn. According to the company, both its HK offering, and international offering were significantly oversubscribed by approx. 164x and 16x respectively.In our previous two insights on the company’s IPO, we discussed the company’s core products and product portfolio, outlook, key financials and the company’s IPO valuation.

Shanghai HeartCare Medical Technology (6609 HK)

Microport MedBot IPO:  Thoughts on First Day Trading